妇科恶性肿瘤患者血清中血管内皮生长因子测定的临床意义

Clinical Significance of Vascular Endothelial Growth Factor in Sera of Patients with Gynaecological Malignant Tumors

背景与目的:实验和临床证明恶性肿瘤的生长、浸润和转移与肿瘤血管生成有关,这过程由多种血管生长因子调控,如血管内皮生长因子(vascularendothelialgrowthfactor,VEGF)。目前在妇科恶性肿瘤患者中测定血清VEGF水平的研究报道不多。本研究测定妇科恶性肿瘤患者血清中VEGF的水平,并探讨其能否成为一种新的肿瘤标记物。材料与方法:采用R&DSystemsIncminneapolisMNUSA生产的QuantikineHumamVEGF试剂盒,用ELISA方法测定50例宫颈癌、39例子宫内膜癌和89例卵巢癌患者的术前血清,以及其中3例卵巢癌术后3、6、9个月及复发时血清的VEGF水平;另用80例健康妇女血清的VEGF水平作为对照。用SPSS9.0统计软件包进行统计分析。用5th和95th位数的区间描述变异程度。结果:80例健康妇女的血清VEGF中位水平为218.5ng/L(42.06-671.70ng/L)。50例宫颈癌、39例子宫内膜癌和89例卵巢癌患者术前血VEGF中位水平分别为272.00ng/L(91.94-745.53ng/L)、383.50ng/L(105.67-776.50ng/L)和479.85ng/L(99.47-1326.88ng/L),子宫内膜癌和卵巢癌患者术前血清VEGF水平显著高于健康妇女(P<0.0001),宫颈癌患者术前血清VEGF与健康妇女相比无显著性差异(P>0.05)。3例卵巢癌患者术后3、6、9个月无复发时测定的血清VEGF水平较术前明显下降。

Background &Objective:Experimental and clinical evidence links tumor growth,invasion,and me tastatic potential with neoangiogenesis.This process is modulated by several an giogenic growth factors,such as vascular endothelial growth factor(VEGF).Few data are currently available on serum level in patients with gynaeco logical malignant tumors This study was designed to determine the s erum VEGF level in the patients with g ynaecological malignant tumors and its significance as a tumor marker.Material &Methods:Preoperative serum VEGF level were measured in 50cervical cancer,39endometrial cancer,89ov arian cancer patients,and 80normal healthy women;The serum VEGF levels were also measured in 3,6,9months after opera tion and when recurrence in three cur ative resection patients with ovarian cancer;using commercially available enzym elinked immonosarbent assay(R&D systems Inc.Minneapolis,MN,USA).Statistical analysis was performed by using the SPSS9.0so ftware package.Using 5th and 95th percentage describe the variant degree.Result:The median level of VEGF in sera of 80h ealthy women was 218.50ng /L(42.06-671.70ng /L),while in 50cervical cancer,39endometrial cancer,and 89ovarian cancer patients were272.00ng /L(91.94-745.53ng /L),383.50ng /L(105.67-776.50ng /L),and 479.85ng /L(99.47-1326.88ng /L),respectively.The VEGF levels in endometrial cancer and ovarian cancer p atients were significantly higher t han that in healthy women(P<0.0001).But in cervical cancer patients the VEGF level,was not significat diffe nt compare with health wanen.After operation,3,6,9months the VEGF levels in 3ovarian c ancer patients were significantly l ower than that of preoperative but it ascended again when the disease was recurrent 14,17months later in two cases.The VEGF l evel was significantly higher in advance d ovarian cancer patients(stageⅢ-Ⅳ)than that in the early stage(stageⅠ-Ⅱ)(P<0.05).Conclusion:The serum level of the VEGF may be used as a new tumor marker of endometrial c ancer and ovarian cancer,for diagnoses and monitorin g the progress of the disease.